Navigation Links
Anthera Announces Data from the Phase 2b PEARL-SC Study Will Be Presented at the 10th International Congress on Systemic Lupus Erythematosus
Date:3/22/2013

domized, double-blind, placebo-controlled, dose-ranging trial to evaluate the safety, tolerability and efficacy of blisibimod plus standard of care, versus placebo plus standard of care.  A total of 547 patients with active SLE were randomized to receive one of three different doses of blisibimod or placebo (100 mg weekly, 200 mg weekly or 200 mg monthly) administered subcutaneously over a minimum 24-week treatment period, in addition to standard-of-care therapy. The study was conducted at multiple centers worldwide. 

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
2. Anthera Pharmaceuticals Announces Departure of Georgina Kilfoil
3. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
4. Anthera Announces Data from the Phase 2b PEARL-SC Study Presented at the 2012 Asian Lupus Summit
5. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
7. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
8. Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
9. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
10. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
11. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... FT LAUDERDALE, Florida , July 1, 2015 /PRNewswire/ ... manufacturer and marketer of innovative medical devices for the treatment ... it prevailed in a final opposition appeal hearing in the ... 482 - STENT HAVING HELICAL ELEMENTS (,482). The ,482 patent ... and has been upheld as a valid patent in amended ...
(Date:7/1/2015)... 1, 2015 Qiming Venture Partners, today announces ... Partner effective immediately. William has been with ... participated in many Qiming healthcare deals, and assisted many ... market. Qiming, s success in healthcare is not a ... himself with his outstanding advocacy and service mentality on ...
(Date:7/1/2015)... , June 24, 2015 ... the addition of the "Future Horizons and ... 2015: Supplier Shares and Country Forecasts" report ... Growth Strategies in the European Blood Banking Market ... order to help current suppliers and potential market ...
Breaking Medicine Technology:OrbusNeich Announces Favorable Ruling from the European Patent Office and Initiation of Litigation Against Terumo Corporation 2Qiming Announces the Promotion of William Hu to Managing Partner 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 2European Blood Banking 2015: Future Horizons and Growth Strategies - Supplier Shares and Country Forecasts 3
... Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), ... Data Safety Monitoring Board (DSMB) recently completed a ... Soligenix,s confirmatory Phase 3 clinical trial of orBec® ... acute gastrointestinal Graft-versus-Host disease (GI GVHD). ...
... CHAPEL HILL, N.C., Sept. 15, 2011 Cempra ... clinical trial investigating the efficacy, safety and tolerability ... solithromycin (CEM-101), a fluoroketolide antibiotic, in comparison with ... pneumonia (CABP).  In the Phase II trial, CEM-101 ...
Cached Medicine Technology:Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 2Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 3Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 4Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 5Soligenix Announces Results of Recent Data Safety Monitoring Board Review for Phase 3 orBec® Study in Acute GI GVHD 6Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 2Cempra Announces Comparable Efficacy of Oral Solithromycin (CEM-101) Compared with Levofloxacin in Phase II Clinical Trial in Patients with Community-Acquired Bacterial Pneumonia (CABP) 3
(Date:7/1/2015)... ... 2015 , ... Sir Fazle Hasan Abed, BRAC’s founder and chairperson, was announced ... been recognised for his outstanding contribution to enhancing the world's production and distribution of ... World Food Prize Foundation, announced this year’s winner at a ceremony at the State ...
(Date:7/1/2015)... ... July 01, 2015 , ... SuiteRx, innovative ... combo, and compounding pharmacy operations, announces the most recent positioning of SuiteRx CEO, ... RBC event at the Venetian Las Vegas, Nevada. During this event, ...
(Date:7/1/2015)... ... July 01, 2015 , ... The Collaborative for Children and Families ... Trust. The grant will allow CCF to improve quality of care and save costs ... formed to respond to many changes in New York’s Medicaid system. Experts agree that ...
(Date:7/1/2015)... ... July 01, 2015 , ... Did you know that infertility ... Health Month, and we at Advanced Fertility Center of Texas (AFCT) would like to ... , While infertility is often considered to be a “woman’s issue,” male fertility factors ...
(Date:7/1/2015)... ... July 01, 2015 , ... “Well-meaning ... Lisa Stolzenberg, a Professor in FIU’s School of International and Public Affairs. ... years who participated in the National Survey on Drug Use and Health, which ...
Breaking Medicine News(10 mins):Health News:Sir Fazle Hasan Abed Receives World Food Prize 2Health News:Sir Fazle Hasan Abed Receives World Food Prize 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 2Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 3Health News:Pharmacy Software Vendor, SuiteRx IPS, Officially Introducing Newly Appointed CEO at Cardinal Health Event in Las Vegas, Nevada 4Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 2Health News:The Collaborative for Children and Families Receives a Grant From The New York Community Trust to Build Capacity for Comprehensive Child Welfare 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 2Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 3Health News:Male Fertility: Improve Testosterone and Fertility With Natural Approaches 4Health News:Researchers find that medical marijuana laws increase recreational marijuana use among juveniles 2
... 28 The one-stop marketplace,for the fine and ... take place at SETEC in Seoul, South Korea, ... range of items in these fields, from,ingredients and ... http://www.newscom.com/cgi-bin/prnh/20080728/NYM070 ), Since its launch ...
... Safety Violations, SALINAS, Calif., July 28 Nursing ... Care Center will,hold a joint demonstration Tuesday asking their ... both of these homes made Windsor,owners over $2 million ... eight Bay Area nursing homes operated by Windsor,Healthcare., ...
... millions of Mexican pesos as of December,31, 2007. Comparisons are ... may vary due to rounding practices. "bp" stands,for basis points), ... - Gross income increased 34.45%, - Gross margin ... as a percentage of sales were 7.19%, - The ...
... Isn,t it odd that cancer cells from one organ, such ... totally different organ, like the lung? , What,s more, why ... to certain places? Prostate cancer usually moves to bone; colon ... Hendrik van Deventer, assistant professor of medicine at the University ...
... Laboratories to Improve ... to Care Across the Country, DAR ES SALAAM, Tanzania, July ... Welfare, United Republic,of Tanzania, and Abbott Fund commemorated the latest step ... cornerstone,for the first of 23 hospital laboratories to be built or ...
... Healthcare, Inc.,(OTC Bulletin Board: TONJ), a premier provider ... it has engaged German,based Dr. Petri Hospital Consulting ... in Nanning, China., Previously, the company reported ... now readjusted architectural and operational plans to,incorporate additional ...
Cached Medicine News:Health News:Most Influential Events for Korea's Fine and Specialty Chemical and Pharmaceutical Industries to be Held in November 2Health News:Most Influential Events for Korea's Fine and Specialty Chemical and Pharmaceutical Industries to be Held in November 3Health News:Most Influential Events for Korea's Fine and Specialty Chemical and Pharmaceutical Industries to be Held in November 4Health News:Caregivers at 8 Bay Area Nursing Homes Protest Unsafe Resident Conditions in Salinas 2Health News:Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively 2Health News:Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively 3Health News:Grupo Casa Saba Announces Sales and Operating Income Increased 14.05% and 13.45%, Respectively 4Health News:Study provides clues to preventing and treating cancer spread 2Health News:Abbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nation's Health Care System 2Health News:Abbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nation's Health Care System 3Health News:Abbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nation's Health Care System 4Health News:Abbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nation's Health Care System 5Health News:Tongji Hires German Based Dr. Petri Consulting GmbH for Langdong Project 2
Quantitative determination of Fibrinogen by STA Analyzers (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
For the quantitative in vitro determination of creatinine in serum, plasma or urine....
For the quantitative in vitro determination of Magnesium in serum, plasma and urine...
Medicine Products: